



HHS Public Access

Author manuscript

Phytochemistry. Author manuscript; available in PMC 2017 February 01.

Published in final edited form as:

Phytochemistry. 2016 February ; 122: 113–118. doi:10.1016/j.phytochem.2015.11.011.

Kalkipyronone B, a marine cyanobacterial γ -pyrone possessing cytotoxic and anti-fungal activities

Matthew J Bertin^a, Ozlem Demirkiran^b, Gabriel Navarro^a, Nathan A Moss^a, John Lee^{a,c}, Gregory M Goldgo^d, Edgar Vigil^d, Elizabeth A Winzeler^d, Fred A Valeriote^e, and William H Gerwick^{a,f,*}

^aCenter for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography, University of California San Diego, 8615 Kennel Way, La Jolla, California 92037, United States

^bDepartment of Pharmacognosy, Faculty of Pharmacy, Trakya University, Edirne, 22030, Turkey

^cChemistry & Biochemistry Program, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92093, United States

^dDepartment of Pediatrics, University of California, San Diego, School of Medicine, 9500 Gilman Drive, La Jolla, California 92093, United States

^eHenry Ford Health System, Department of Internal Medicine, Josephine Ford Cancer Center, 440 Burroughs, Room 415, Detroit, MI 48202, United States

^fSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92093, United States

Abstract

Bioassay-guided fractionation of two marine cyanobacterial extracts using the H-460 human lung cancer cell line and the OVC-5 human ovarian cancer cell line led to the isolation of three related α -methoxy- β , β' -dimethyl- γ -pyrones each containing a modified alkyl chain, one of which was identified as the previously reported kalkipyronone and designated kalkipyronone A. The second compound was an analog designated kalkipyronone B. The third was identified as the recently reported yoshiopyronone A, also isolated from a marine cyanobacterium. Kalkipyronone A and B were obtained from a field-collection of the cyanobacterium *Leptolyngbya* sp. from Fagasa Bay, American Samoa, while yoshiopyronone A was isolated from a field-collection of cyanobacteria (cf. *Schizothrix* sp.) from Panama. One-dimensional and two-dimensional NMR experiments were used to determine the overall structures and relative configurations of the kalkipyronones, and the absolute configuration of kalkipyronone B was determined by ¹H NMR analysis of diastereomeric Mosher's esters. Kalkipyronone A showed good cytotoxicity to H-460 human lung cancer cells

*Corresponding author. Tel: (858) 534-0578; fax: (858) 534-0576, wgerwick@ucsd.edu, *Mailing address*: Scripps Institution of Oceanography, University of California San Diego, Center for Marine Biotechnology and Biomedicine, 8615 Kennel Way, Sverdrup Hall, Room 3232, La Jolla, California 92037.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Supplementary data

Supplementary data associated with this article can be found in the online version.

($EC_{50} = 0.9 \mu\text{M}$), w M), while kalkipyronone B and yoshiopyronone A were less active ($EC_{50} = 9.0 \mu\text{M}$ and $> 10 \mu\text{M}$, respectively). Both kalkipyronone A and B showed moderate toxicity to *Saccharomyces cerevisiae* ABC16-Monster strain ($IC_{50} = 14.6$ and $13.4 \mu\text{M}$, respectively), whereas yoshiopyronone A was of low toxicity to this yeast strain ($IC_{50} = 63.8 \mu\text{M}$).

Keywords

cyanobacteria; polyketide; kalkipyronone; yoshiopyronone; *Leptolyngbya*; *Moorea*; *Schizothrix*

1. Introduction

Cyanobacteria are prolific producers of secondary metabolites, namely compounds which are not used for growth, structure or reproduction. These structurally diverse substances have displayed intriguing bioactivities (Nunnery et al., 2010; Tan, 2007) and their continued discovery remains an important pipeline in the development of therapeutic agents (Simmons et al., 2008; Tan, 2005). Many of these compounds arise from either polyketide synthases (PKS), nonribosomal peptide synthetases (NRPS), or hybrids of these two pathways. Unique arrangements of modifying enzymatic machinery in these modular pathways gives rise to a varied array of natural products. Moreover, enzymatic reactions at the terminal end of these pathways create rings of different sizes, (Jones et al., 2010) side-chains of varying length, or terminal unsaturations (Chang et al., 2004; Edwards et al., 2004). The diversity of resulting functionalities can provide target selectivity as well as favorable pharmacokinetic properties to polyketide molecules (Driggers et al. 2008).

Kalkipyronone, a polyketide natural product featuring a α -pyrone, was originally isolated from a mixed assemblage of *Moorea producens* (formerly *Lyngbya majuscula*) and *Tolypothrix* sp. collected from the splash zone at Playa Kalki, Curaçao (Graber and Gerwick, 1998). This compound showed toxicity to brine shrimp ($1 \mu\text{g/mL}$) and goldfish ($2 \mu\text{g/mL}$) and was structurally related to the actinopyrones, which were obtained from a *Streptomyces* sp. (Yano et al., 1986a; Yano et al., 1986b). The actinopyrones have displayed a diverse suite of bioactivities including anti-microbial, cytotoxicity, vasodilating properties, and EGF signaling inhibitory properties (Schleissner et al., 2011; Yano et al., 1986). Aureothin, isolated from *S. spectabilis*, features a α -pyrone with a tetrahydrofuran-containing aryl polyene side chain and has displayed significant anti-fungal and anti-proliferative activity (Werneberg et al., 2010). The neofusapyrones and dactylfungins are pyrone-containing polyketides isolated from fungi with antifungal activity (Honma et al., 2010; Xaio et al., 1993). The structures of the yoshiopyrones, kalkipyronone analogs from a field-collected *Leptolyngbya* sp., have recently been characterized and yoshiopyronone A was shown to inhibit adipogenic differentiation in 3T3-L1 cells (Inuzuka et al., 2014).

In this work, reported are the re-isolation of kalkipyronone A (**1**) and yoshiopyronone A (**3**), and the structure characterization of a new analog, kalkipyronone B (**2**), all of which are polyketides featuring a pyrone head group and side-chains with varying levels of unsaturation. Kalkipyronone A (**1**) and B (**2**) were isolated from a cyanobacterium of the *Leptolyngbya* lineage collected from American Samoa, whereas yoshiopyronone A (**3**) was

isolated from a field-collection of the cyanobacterium cf. *Schizothrix* sp. from Panama. The structures of these compounds were determined using 1D and 2D NMR techniques, in addition to subsequent spectroscopic and spectrometric techniques. The absolute configuration of kalkipyronone B (**2**) was determined by a modified Mosher's ester method (Hoye et al., 2007). These kalkipyronones were evaluated for cytotoxicity against the H-460 human lung cancer cell line and the *Saccharomyces cerevisiae* ABC16-Monster strain. Kalkipyronone A (**1**) was the most potent to H-460 cells ($EC_{50} = 0.9 \mu\text{M}$), while kalkipyronone B (**2**) was less active ($EC_{50} = 9.9 \mu\text{M}$), and yoshiipyronone A (**3**) showed little cytotoxicity to this cell line. Kalkipyronone A (**1**) and B (**2**) also showed moderate cytotoxicity to *S. cerevisiae* ABC16-Monster whereas yoshiipyronone A (**3**) was essentially inactive against this strain.

2. Results and discussion

Bioassay-guided fractionation using the H-460 human lung cancer cell line led to the isolation of one minor and one major metabolite from a collection of cyanobacteria biomass from Fagasa Bay, American Samoa (Supplemental Fig. 1). HRESIMS of the minor metabolite (**1**) gave an $[M + Na]^+$ at m/z 355.1883 suggesting a molecular formula of $C_{20}H_{28}O_4$ and a requirement of seven degrees of unsaturation. Examination of two-dimensional NMR data, the IR spectrum, and UV absorbance (see Supplementary data) led to the identification of this minor metabolite as kalkipyronone (Graber and Gerwick, 1998). Here, this originally described 'kalkipyronone' is designated as 'kalkipyronone A' (**1**) (Fig. 1).

HRESIMS of the major compound **2** gave an $[M + Na]^+$ at m/z 357.2035, suggesting a molecular formula of $C_{20}H_{30}O_4$ and a requirement for six degrees of unsaturation. Examination of the ^1H NMR spectrum of **2** (Supplemental Fig. 2) suggested a compound related to kalkipyronone A (**1**) with a less complex olefinic proton region. One doublet and four singlet 3H peaks (δ 1.00–2.00) and one deshielded 3H singlet (δ 3.93) suggested a total of six methyl groups, one of which was an *O*-methyl. Three high-field methylene resonances (δ 1.52, 1.93 and 2.00) and one deshielded methylene (δ 3.29) doublet were also observed. The remaining proton resonances included a deshielded methine proton (δ 4.58) and two olefinic proton resonances (δ 5.20 and 5.21).

HSQC, HMBC, COSY and TOCSY correlations (Fig. 2, Table 1, Table S1 and Supplemental Figs. 4–8) were used to determine the structure of **2**. The oxymethine at H-14 showed HMBC correlations to C-12 and C-13 and COSY correlations to H-13 and H-15 placing it adjacent to a methyl group and an olefin. The olefin proton H-13 showed HMBC correlations to the methylene C-11 and methyl C-16. In turn, the H-16 methyl protons showed HMBC correlations to the quaternary carbon at C-12 (δ 137.4), confirming the presence of a methyl substituted olefin. Bidirectional HMBC correlations, COSY correlations, ^1H NMR splitting patterns and δ ^1H and ^{13}C values established the presence of three methylene groups between C-12 and C-8. HMBC correlations from H-7 and H₃-17 to C-8 supported a second methyl substituted olefin. While these two olefin proton signals were overlapped (δ 5.20, 5.21) in the CDCl_3 ^1H NMR spectrum, a second ^1H NMR in DMSO (Supplemental Fig. 3) showed H-7 as a triplet (δ 5.25) and H-13 to be a doublet (δ 5.07), as expected for **2**. The deshielded H₂-6 methylene protons showed HMBC correlations to both C-7 and the quaternary carbon C-5, demonstrating a side-chain nearly

identical to **1** with the exception of a fully saturated bond between C-10 and C-11 for **2**. The ^{13}C chemical shift of C-5 (δ 157.2) was in agreement with an olefinic carbon attached to an electron-withdrawing group; this was further supported by observation of an HMBC correlation between H₂-6 and C-1 in a Long Range HMBC experiment (LR HMBC; ^1H - ^{13}C $J = 4$ Hz), suggesting a pyrone moiety in **2** as in **1**. This was confirmed by HMBC correlations between the H₃-18 methyl protons and C-3, C-4 and C-5. Complementing this, the H₃-19 methyl protons showed HMBC correlations to C-1, C-2 and C-3. An HMBC correlation between the H₃-20 methoxy protons and C-1 located this functionality and completed the planar structure of kalkipyronone B (**2**).

The geometries of the two olefinic bonds in **2** were determined using NOESY correlations (Supplemental Fig. 9). NOE correlations from H-13 to H₂-11, in addition to correlations between H-14 and the H₃-16, supported assignment of the position 12–13 double bond in the *E* configuration. Similarly, NOE correlations between H₂-6 and H₃-17 and between H-7 and H₂-9 supported assignment of the position 7, 8 olefin as having an *E* configuration, the same as in kalkipyronone A (**1**).

The absolute configuration of **2** was determined using a modified Mosher's esterification protocol (Hoye et al., 2007), in which two equal portions of **2** were acylated with *R*-(-)- and *S*-(+)- α -methoxy- α -(trifluoromethyl)phenylacetyl chloride (MTPA-Cl). This yielded the C-14 *R*-ester from (*S*)-MTPA-Cl and the C-14 *S*-ester from (*R*)-MTPA-Cl. The ^1H NMR spectra of the diastereomeric MTPA esters were examined (Supplemental Figs. 10 and 11) and ^1H resonances assigned for each ester so as to calculate α (δS - δR) values. A positive value for H-15 and negative values for H-14, H-13, H-12, and H-16 supported a 14*R* configuration, again the same as in kalkipyronone A (**1**) (Fig. 1).

A cyanobacterial collection from Panama was extracted and fractionated by VLC and a relatively polar fraction ('H' eluting with 75% EtOAc in MeOH) showed potent and selective toxicity to the OVC-5 human ovarian cancer cell line. Semi-preparative HPLC of this active fraction yielded **3** which gave by HRESIMS an $[\text{M} + \text{Na}]^+$ at m/z 387.2146, suggesting a molecular formula of C₂₁H₃₂O₅ with six degrees of inherent unsaturation. Comparison of the molecular formulas of **1**, **2** and **3**, along with the presence of a new deshielded 3H singlet (δ 3.15) in the ^1H NMR spectrum of **3** (cf. Supplemental Figs. 1 A and 1 C), suggested the presence of a second *O*-methyl group within a kalkipyronone framework. Examination of the 2D NMR data confirmed the position of the *O*-methyl group as attached to C-11. The remaining correlations surrounding the *O*-methyl position were identical to **1** and **2** and confirmed the structure of **3** as that of yoshiopyronone A (Fig. 1) (Inuzuka et al., 2014).

Comparison of the cytotoxicity for these three related metabolites showed interesting relationships. Kalkipyronone A (**1**) with an unsaturation between C-10 and C-11 is the most potent cytotoxic compound, and saturation of this position as in **2** reduces the activity 10-fold (Supplemental Fig. 12). The addition of the methoxy subunit to C-11 as in **3** reduces the cytotoxicity even further. It thus appears that the cytotoxicity properties of the kalkipyronones show distinct structure-activity relationships (SAR), and it would thus be interesting to explore the biological properties of synthetic analogs in this structure class. In this regard,

the secondary alcohol of kalkipyronone B (**2**) could serve as a site for chemical modification (Marel et al., 2008; Gopalakrishnan et al., 1997). As such, an acetyl group was synthetically added to kalkipyronone B (**4**), but the resulting derivative kalkipyronone B acetate (**4**) showed no cytotoxic effects even at the highest concentrations tested (50 μM). This observation is consistent with the activity profile of **1**, **2** and **3**. The addition of acyl groups to the pyrone side chain (*O*-methylation in **3** and acetylation in **4**) appears to inhibit cytotoxic activity. It will be interesting to observe if these structure-activity relationships extend to other types of biological activity. For example, the nocayrones B, H and L, γ -pyrone containing polyketides from marine *Nocardioopsis* strains, were recently shown to be Ca^{2+} channel modulators (Ochoa et al., 2015; Kim et al., 2014).

The 'ABC16-Monster' is a genetically engineered strain of *Saccharomyces cerevisiae* from which sixteen multi-drug resistance pump genes have been deleted (Suzuki et al., 2011). These deletions make it more sensitive to chemical agents than other laboratory yeast strains (Suzuki et al., 2011). As a result, the ABC16-Monster strain is useful for studies exploring a compound's mechanism of action (MOA). In addition, drug sensitivity of the ABC16-Monster strain parallels that of neoplastic cells, indicating that it is a good surrogate for MOA studies. When tested against *S. cerevisiae* ABC16-Monster, **1** and **2** showed nearly the same moderate cytotoxicity (IC_{50} : **1** = 14.6 μM ; **2** = 13.4 μM). Yoshiopyrone A (**3**) showed little cytotoxicity (IC_{50} = 63.8 μM) (Supplemental Fig. 13), consistent with previous results (Liang et al., 2014). While **3** was isolated from a fraction which showed potent activity to OVC-5 human ovarian cancer cells, we were not able to isolate enough material for retesting of pure yoshiopyrone A against this cell line, and it remains possible that other metabolites in this fraction were responsible for the observed OVC-5 cytotoxicity.

Live specimens of ASG15JUL14-6 were returned to the laboratory from American Samoa. These cultures were predominately comprised of thin reddish filaments (see Supplementary data for photomicrograph of voucher specimen); by microscopy these were identified as *Leptolyngbya* sp. Thicker filaments, provisionally identified as *Moorea* sp., were a very minor component of this collection. Unfortunately, the *Leptolyngbya* component of this collection was not successfully adapted to laboratory culture. Nevertheless, based on its relative prevalence in the collection, *Leptolyngbya* is most certainly the source of the kalkipyrones A (**1**) and B (**2**) reported herein.

Because many cyanobacterial species have overlapping morphological characteristics, a genetic analysis was applied using a voucher specimen of the field-collected cyanobacteria preserved in RNAlater solution. DNA was isolated from this specimen, the 16S rRNA gene was amplified by PCR and a subcloning procedure was performed. The 16S rRNA sequences of all five clones showed >99% identity to each other and BLAST searching showed highest identity (95%) to sequences from *Oscillatoria* sp., *Leptolyngbya* sp. and *Trichocoleus* sp. Phylogenetic analysis of the consensus 16S rRNA gene sequence of ASG15JUL14-6 (1410 bp) placed it in the *Leptolyngbya* clade (Figure 3). However, it clustered most closely with *Oscillatoria genimata* SAG 1459-8 within the *Leptolyngbya* clade. *O. genimata* SAG 1459-8 does not cluster with other *Oscillatoria* strains and this may indicate its reassignment as a *Leptolyngbya* strain. Summarizing, the morphological and

phylogenetic evidence support a taxonomic classification of the kalkipyronone A (1) and B (2) producer from American Samoa as a *Leptolyngbya* sp.

The field-collection of cyanobacteria from Panama from which yoshinone (3) was isolated was morphologically identified as a *Schizothrix* sp. Kalkipyronone A (1) was originally isolated from a mixed collection of *Moorea* sp. and *Tolypothrix* sp. from Playa Kalki, Curaçao, whereas yoshipyrone A (3) was isolated from a sample of *Leptolyngbya* sp. collected from Ishigaki island, Okinawa, Japan. However, all of these identifications were based on morphological characteristics. To our knowledge, the report herein is the first to incorporate phylogenetic analysis into the identification of a kalkipyronone-producing cyanobacterium, firmly establishing it as a *Leptolyngbya* sp.

3. Concluding remarks

In summary, one new and two known kalkipyronone-type metabolites were isolated from two field-collections of marine cyanobacteria. Kalkipyronone A (1) and B (2) showed cytotoxicity against human lung cancer cells and yeast cells. The geographic distribution of the kalkipyronones from multiple sites in the Caribbean and North and South Pacific Ocean generates intriguing questions concerning the ecological and physiological role of these molecules in cyanobacteria.

4. Experimental

4.1. General procedures

Optical rotations were measured on a JASCO P-2000 polarimeter, UV spectra on a Beckman Coulter DU-800 spectrophotometer, and IR spectra with a Nicolet IR-100 FT-IR spectrophotometer with a KBr plate. NMR spectra were recorded with residual CHCl_3 as the internal standard (δ_{C} 77.0, δ_{H} 7.26) on a Varian Unity 500 MHz spectrometer. A Bruker 600 MHz spectrometer equipped with a 1.7 mm MicroCryoProbe was also used for some experiments. Semi-preparative HPLC was carried out using a Waters 515 pump system equipped with a Waters 996 PDA. Isolated HPLC peaks were subjected to LC-MS/MS analysis using a ThermoFinnigan LCQ AdvantageMax mass detector equipped with an electrospray ionization (ESI) source. High resolution electrospray ionization mass spectra (HRESIMS) were obtained using an Agilent 1290 Infinity system with an Agilent 6530 Accurate Mass Q-TOF LC/MS.

4.2. Collection and morphological identification of cyanobacteria

Kalkipyronone-producing cyanobacteria were collected from Panama (PAP25JUN12-1) and from Fagasa Bay, American Samoa (ASG15JUL14-6) by hand using SCUBA. Voucher specimens under these collection codes are stored in the Scripps Institution of Oceanography marine cyanobacterial voucher collection, and are available from the corresponding author. Biomass was collected in a 1 L bottle and preserved in seawater:iPrOH (1:1) solution for subsequent extraction. Live specimens were brought back to the laboratory and examined using an Olympus IX51 epifluorescent microscope equipped with an Olympus U-CMAD3 camera for morphological identification.

4.3. Extraction and isolation of kalkipyrones

The cyanobacteria biomass collected from Fagasa Bay, American Samoa (ASG15JUL14-6) was repeatedly extracted using CH₂Cl₂-MeOH (2:1), affording a 1 g crude extract. The latter was further fractionated over silica gel using vacuum liquid chromatography (VLC) and a solvent system of increasing polarity using a stepped gradient of hexanes, EtOAc and MeOH. Fractions F (EtOAc-hexanes, 5:1), G (EtOAc), and H (EtOAc-MeOH, 4:1) were combined (63.6 mg) and separated into 5 fractions using C18 SPE (1 g) and a stepwise gradient solvent system starting with MeCN-H₂O (4:1) and ending with CH₂Cl₂. Fractions 1 (MeCN-H₂O, 4:1) and Fraction 2 (MeCN) were combined (13.7 mg) and subjected to RP semi-preparative HPLC using a Phenomenex 4 μm Hydro column (250 × 10 mm) with a gradient from H₂O-MeCN (1:1) to MeCN over 20 minutes yielding kalkipyronone A (**1**) (1 mg) and kalkipyronone B (**2**) (2.5 mg). The cyanobacterial biomass from Panama was extracted and fractionated by VLC as described above and Fraction H (EtOAc-MeOH, 4:1) was subjected to RP semi-preparative HPLC yielding yoshiipyronone A (**3**) (0.3 mg).

Kalkipyronone B (2): yellow oil; $[\alpha]_D^{25} +9.3$ (*c* 0.2, CHCl₃); UV (MeOH) α_{\max} (log α) 249 nm; IR (DCM, neat) α_{\max} 3395, 2928, 2852, 1664, 1581, 1464, 1403, 1375, 1334, 1251, 1162, 1059, 983, 967, 764, 482 cm⁻¹; for ¹H NMR (500 MHz, CDCl₃) and ¹³C NMR (500 MHz, CDCl₃) spectroscopic data, see Table 1; HRESIMS [M + Na]⁺ *m/z* 357.2035 (calcd for C₂₀H₃₀O₄, 357.2036).

4.4 Preparation of kalkipyronone B (2) MTPA esters

Compound **2** (0.5 mg) was reconstituted in CH₂Cl₂ (0.5 mL) in a 2 mL vial to which dry pyridine (5 μL) and (*S*)-(-)- α -methoxy- α -(trifluoromethyl)phenylacetyl chloride (7 μL) were added. The vial was capped and the reaction was stirred for 15 h. The identical procedure was repeated with an equal amount of **2** and (*R*)-(+)- α -methoxy- α -(trifluoromethyl)phenylacetyl chloride. The reaction mixtures were quenched with H₂O and extracted with CH₂Cl₂. The preparation was purified over a silica SPE column (50 mg) eluting with EtOAc-hexanes (1:1). **R ester**: partial ¹H NMR (500 MHz, CDCl₃) δ 5.85 (1H, m, H-14), 5.21 (1H, m, H-7), 5.19 (1H, m, H-13), 3.92 (3H, s, H-20), 3.30 (2H, d, *J* = 7.1 Hz, H-6), 2.06 (2H, m, H-9), 1.99 (2H, m, H-11), 1.97 (3H, s, H-19), 1.85 (3H, s, H-18), 1.75 (3H, s, H-17), 1.71 (3H, s, H-16), 1.52 (2H, m, H-10), 1.31 (3H, d, *J* = 6.3 Hz, H-15). **S-ester**: partial ¹H NMR (500 MHz, CDCl₃) δ 5.82 (1H, m, H-14), 5.17 (1H, t, *J* = 7.1 Hz, H-7), 5.08 (1H, d, *J* = 9.0 Hz, H-13), 3.92 (3H, s, H-20), 3.30 (2H, d, *J* = 7.1 Hz, H-6), 1.99 (2H, m, H-9), 1.97 (3H, s, H-19), 1.95 (2H, m, H-11), 1.87 (3H, s, H-18), 1.73 (3H, s, H-17), 1.70 (3H, s, H-16), 1.49 (2H, m, H-10), 1.38 (3H, d, *J* = 6.4 Hz, H-15).

4.5 Acetylation of kalkipyronone B

A sample of **2** (0.4 mg) was stirred for 24 h in a 1:1 solution of pyridine:Ac₂O. The reaction mixture was dried under N₂ and partitioned between CH₂Cl₂ and H₂O, following which the CH₂Cl₂ layer was removed and dried under N₂. The residue was reconstituted in MeCN and subjected to RP-HPLC using a Phenomenex 4 μm Hydro column (250 × 10 mm) and an isocratic solvent system of MeCN-H₂O (9:1). Kalkipyronone B acetate (**4**) (0.2 mg isolated) eluted at 11 min.

Kalkipyronone B acetate (**4**): pale yellow oil; $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 5.59 (1H, m, H-14), 5.21 (1H, t, $J = 7.3$ Hz, H-7), 5.13 (1H, d, $J = 8.7$ Hz, H-13), 3.94 (3H, s, H-20), 3.30 (2H, d, $J = 7.3$ Hz, H-6), 2.02 (3H, s, H-22), 1.99 (2H, m, H-11), 1.96 (3H, s, H-18), 1.94 (2H, m, H-9), 1.85 (3H, s, H-19), 1.72 (3H, s, H-17) 1.69 (3H, s, H-16) 1.52 (2H, m, H-10), 1.25 (3H, d, $J = 6.5$ Hz, H-15); $^{13}\text{C NMR}$ (600 MHz, CDCl_3) δ 180.9 (C, C-3), 170.3 (C, C-21), 162.0 (C, C-1), 157.0 (C, C-5), 139.0 (C, C-12), 138.8 (C, C-8), 125.0 (CH, C-13), 118.0 (C, C-4), 117.4 (CH, C-7), 99.3 (C, C-2), 68.0 (CH, C-14), 55.1 (CH_3 , C-20), 38.9 (CH_2 , C-9), 38.8 (CH_2 , C-11), 29.9 (CH_2 , C-6), 25.7 (CH_2 , C-10), 21.3 (CH_3 , C-22), 20.7 (CH_3 , C-15), 16.4 (CH_3 , C-16), 16.2 (CH_3 , C-17), 9.8 (CH_3 , C-18), 6.8 (CH_3 , C-19); HRESIMS [$\text{M} + \text{Na}$] $^+$ m/z 399.2147 (calcd for $\text{C}_{22}\text{H}_{32}\text{O}_5$, 399.2142).

4.6. Cytotoxicity assay

Human lung cancer H-460 cells were added to 96-well plates at 3.33×10^4 cells/mL in Roswell Park Memorial Institute (RPMI) 1640 media with fetal bovine serum (FBS) and 1% penicillin/streptomycin. The cells were incubated overnight (37 °C, 5% CO_2) in a volume of 180 μL L per well to allow recovery before treatment with test compounds. The test substances were dissolved in DMSO to a stock concentration of 1 mg/mL. Working solutions were made through serial dilution in RPMI 1640 media without FBS, with 20 μL added to each well to produce final compound concentrations of 10, 3, 1, 0.3, 0.1, 0.03, 0.01, 0.003, and 0.001 $\mu\text{g}/\text{mL}$. An equal volume of RPMI 1640 media without FBS was added to wells designated as negative controls for each plate. Plates were incubated for approximately 48 h before MTT staining (Mosmann, 1983). Plates were read at 570 and 630 nm using a ThermoElectron Multiskan Ascent plate reader to determine cell viability (Mosmann, 1983).

4.7. Yeast cytotoxicity assay

S. cerevisiae ABC16-Monster cells were inoculated from single colonies grown on agar plates stored at 4 °C into 2 mL of synthetic complete minimal media in 5 mL snap-cap culture tubes. The tubes were then incubated overnight at 250 RPM in a shaking incubator (Controlled Environment Incubator Shaker, Model G-25, New Brunswick Scientific Co., Inc.). Cultures were removed in mid-log phase (OD_{600} reading between 0.1 and 0.5) and the cells were then diluted to OD_{600} 0.01. Aliquots of cells (30 μL) were added to a 384 well plate. Kalkipyronone A (**1**) and B (**2**) and yoshiipyronone A (**3**) were reconstituted in DMSO (1.5%) at a starting concentration of 150 or 300 μM and fifteen serial dilutions (1:2) were performed for dosing. An initial OD_{600} reading was performed at time 0 and then the plate was covered with a lid in an incubator at 30 °C for 18 hr. The plates were shaken for 1 min on the 'high' setting in a Synergy HT spectrophotometer and then an OD_{600} measurement was immediately recorded.

IC_{50} values were determined by subtracting OD_{600} measurement at time 0 hr from that at 18 hr. Nonlinear regression was performed on the log (inhibitor) vs. response using the variable slope model. Minimum values are constrained to 0.0 in case any compounds have a higher OD value at time 0 hr than at 18 hr. For each determined IC_{50} value, three experimental replicates of two technical duplicates were performed. Fold changes in IC_{50} values were compared using a one-way ANOVA, followed by Dunnett's post-hoc test when comparing multiple treatments to a control treatment.

4.8. DNA extraction, amplification, sequencing and phylogenetic analysis

Wet biomass of field-collected cyanobacterial tissue (*ca.* 5 g) from American Samoa were stored in RNA-preserving reagent RNeasy lysis solution (Qiagen), comprising two finger-sized tufts of cyanobacteria. Half of the sample was frozen using liquid N₂ and ground via mortar and pestle into a powder. The pulverized frozen biomass was then subjected to the G20 Genomic Tip - Qiagen bacterial DNA isolation protocol following the manufacturer's instructions (Qiagen). Primers used to amplify 16S rRNA sequences were GGGGAATYTTCCGCAATGGG (forward) and GGCTACCTTGTTACGACTT (reverse) (Nubel et al., 1997; Martinez-Murcia et al., 1995). The PCR reaction contained 2X Taq Master Mix (12.5 µL) (Promega), H₂O (10 µL), forward and reverse primers (1 µL) at a final primer concentration of 0.4 µM, and DNA (1 µL) (~50 ng). The PCR cycling conditions were as follows: 95 °C for 1.5 min initial denaturation, followed by 35 cycles of 95 °C denaturation for 30 s, 50.5 °C annealing for 30 s, 72 °C for 2 min, with a final extension time of 4 min. PCR products were cloned via the TOPO-TA cloning kit (Life Technologies) into DH5α *E. coli* as per manufacturer's instructions, grown overnight, then transferred into liquid media and grown overnight. Plasmids from five clones were harvested using the QIAprep Spin Miniprep kit (Qiagen), and Sanger sequenced with M13 primers. The 16S rRNA sequence of ASG15JUL14-6 was aligned with other cyanobacterial 16S rRNA genes using MUSCLE. The evolutionary history was inferred by using the Maximum Likelihood method based on the General Time Reversible model. A bootstrap consensus tree was inferred from 1000 replicates. Sequence alignments and phylogenetic trees were constructed in MEGA v. 5.2.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank E. Glukhov for photomicrographs of the voucher specimen of *Leptolyngbya* sp. (ASG15Jul14-6). O. Demirkiran is grateful to The Scientific and Technological Research Council of Turkey (TUBITAK) for a fellowship that enabled her to conduct research at the Scripps Institution of Oceanography, UCSD. This work was supported by NIH Grants TW006634 and CA100851 (to WHG).

References

- Chang C, Sitachitta N, Rossi JV, Roberts MA, Flatt PM, Jia J, Sherman DH, Gerwick WH. Biosynthetic pathway and gene cluster analysis of curacin A, an antitubulin natural product from the tropical marine cyanobacterium *Lyngbya majuscula*. *J. Nat. Prod.* 2004; 67:1356–1367. [PubMed: 15332855]
- Driggers EM, Hale SP, Lee J, Terrett NK. The exploration of macrocycles for the drug discovery—an underexploited structural class. *Nat. Rev. Drug Discov.* 2008; 7:608–624. [PubMed: 18591981]
- Edwards DJ, Marquez BL, Nogle LM, McPhail K, Goeger DE, Roberts MA, Gerwick WH. Structure and biosynthesis of the jamaicamides, new mixed polyketide-peptide neurotoxins from the marine cyanobacterium *Lyngbya majuscula*. *Chem. Biol.* 2004; 11:817–833. [PubMed: 15217615]
- Gopalakrishnan G, Banumathi B, Suresh G. Evaluation of the antifungal activity of natural xanthenes from *Garcinia mangostana* and their synthetic derivatives. *J. Nat. Prod.* 1997; 60:519–524. [PubMed: 9213587]

- Graber MA, Gerwick WH. Kalkipyron, a toxic gamma-pyrone from an assemblage of the marine cyanobacteria *Lyngbya majuscula* and *Tolypothrix* sp. *J. Nat. Prod.* 1998; 61:677–680. [PubMed: 9599278]
- Honma M, Kudo S, Takada N, Tanaka K, Miura T, Hashimoto M. Novel neofusapyrones isolated from *Verticillium dahlia* as potent antifungal substances. *Bioorg. Med. Chem. Lett.* 2010; 20:709–712. [PubMed: 19962895]
- Hoye T, Jeffrey CS, Shao F. Mosher ester analysis for the determination of absolute configuration of the stereogenic (chiral) carbinol carbons. *Nat. Protoc.* 2007; 2:2451–2458. [PubMed: 17947986]
- Inuzuka T, Yamamoto K, Iwasaki A, Ohno O, Suenaga K, Kawazoe Y, Uemura D. An inhibitor of the adipogenic differentiation of 3T3-L1 cells, yoshinone A, and its analogs, isolated from the marine cyanobacterium *Leptolyngbya* sp. *Tetrahedron Lett.* 2014; 55:6711–6714.
- Jones AC, Monroe EA, Eisman EB, Gerwick L, Sherman DH, Gerwick WH. The unique mechanistic transformations involved in the biosynthesis of modular natural products from marine cyanobacteria. *Nat. Prod. Rep.* 2010; 27:1048–1065. [PubMed: 20442916]
- Kim Y, Ogura H, Akasaka K, Oikawa T, Matsuura N, Imada C, Yasuda H, Igarashi Y. Nocapyrones: α - and α -pyrones from a marine-derived *Nocardiosis* sp. *Marine Drugs.* 2014; 12:4110–4125. [PubMed: 25007160]
- Marel AK, Lizard G, Izard JC, Latruffe N, Delmas D. Inhibitory effects of trans-resveratrol analog molecules on the proliferation and the cell cycle progression of human colon tumoral cells. *Mol. Nutr. Food Res.* 2008; 52:538–548. [PubMed: 18384089]
- Martínez-Murica AJ, Acinas SG, Rodríguez-Valera F. Evaluation of prokaryotic diversity by restrictase digestion of 16S rDNA directly amplified from hypersaline environments. *FEMS Microbiol. Ecol.* 1995; 17:247–255.
- Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. *J. Immunol. Methods.* 1983; 65:55–63. [PubMed: 6606682]
- Nübel U, Garcia-Pichel F, Muyzer G. PCR primers to amplify 16S rRNA genes from cyanobacteria. *Appl. Environ. Microbiol.* 1997; 63:3327–3332. [PubMed: 9251225]
- Nunnery JK, Mevers E, Gerwick WG. Biologically active secondary metabolites from marine cyanobacteria. *Curr. Opin. Biotechnol.* 2010; 21:787–793. [PubMed: 21030245]
- Ochoa JL, Bray WM, Lokey RS, Linington RG. Phenotype-guided natural products discovery using cytological profiling. *J. Nat. Prod.* 2015 In press.
- Schleissner C, Pérez M, Losada A, Rodríguez P, Crespo C, Zúñiga P, Fernández R, Reyes F, de la Calle F. Antitumor actinopyrones produced by *Streptomyces ablus* POR-04-15-053 isolated from a marine sediment. *J. Nat. Prod.* 2011; 74:1590–1596. [PubMed: 21718029]
- Simmons TL, Coates RC, Clark BR, Engene N, Gonzalez D, Esquenazi E, Dorrestein PC, Gerwick WH. Biosynthetic origin of natural products isolated from marine organism-invertebrate assemblages. *Proc. Natl. Acad. Sci. USA.* 2008; 105:4587–4594. [PubMed: 18250337]
- Suzuki Y, St. Onge RP, Mani R, King OD, Heilbut A, Labunskyy VM, Chen W, Pham L, Zhang LV, Tong AH, Nislow C, Giaever G, Gladyshev VN, Vidal M, Schow P, Lehár J, Roth FP. Knocking out multigene redundancies via cycles of sexual assortment and fluorescence selection. *Nat. Methods.* 2011; 8:159–164. [PubMed: 21217751]
- Tan LT. Bioactive natural products from marine cyanobacteria for drug discovery. *Phytochemistry.* 2007; 68:954–979. [PubMed: 17336349]
- Tan LT. Pharmaceutical agents from filamentous marine cyanobacteria. *Drug Discov. Today.* 2005; 18:863–871. [PubMed: 23711931]
- Werneburg M, Busch B, He J, Richter MEA, Xiang L, Moore BS, Roth M, Dahse H, Hertweck C. Exploiting enzymatic promiscuity to engineer a focused library of highly selective antifungal and antiproliferative aureothin analogues. *J. Am. Chem. Soc.* 2010; 132:10407–10413. [PubMed: 20662518]
- Xiao J, Kumazawa S, Yoshikawa N, Mikawa T, Sato Y. Dactylfungins, novel antifungal antibiotics produced by *Dactylaria parvispora*. *J. Antibiotics.* 1993; 46:48–55. [PubMed: 8436559]
- Yano KK, Yokoi K, Sato J, Oono J, Kouda T, Ogawa Y, Nakashima T. Actinopyrones A, B and C, new physiologically active substances. I. Producing organism, fermentation, isolation, and biological properties. *J. Antibiotics.* 1986a; 39:32–37. [PubMed: 3753969]

Yano KK, Yokoi K, Sato J, Oono J, Kouda T, Ogawa Y, Nakashima T. Actinopyrones A, B and C, new physiologically active substances. II. Physico-chemical properties and chemical structures. J. Antibiotics. 1986b; 39:38–43. [PubMed: 3753970]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Highlights

- Bioassay guided isolation gave three γ -pyrones from a marine cyanobacterium
- Kalkipyronone B was determined by NMR and Mosher's ester analysis
- Kalkipyronone A was cytotoxic while kalkipyronone A and B were equipotent antifungals
- 16S rRNA analysis identified the producing strain to be a *Leptolyngbya* species




Fig. 1.
Chemical structures of compounds 1–4




Fig. 2.
Selected HMBC (black arrows) and COSY (dashed arrows) correlations for kalkipyron B (2).




Fig. 3. Phylogenetic analysis of the kalkipyronone producing strain ASG15JUL14-6 (American Samoa collection), which is embedded within the *Leptolyngbya* sp. clade. The evolutionary history was inferred by using the Maximum Likelihood method based on the General Time Reversible model. The bootstrap consensus tree is inferred from 1000 replicates. Branches corresponding to partitions reproduced in less than 0% bootstrap replicates are collapsed. The percentage of replicate trees in which the associated taxa clustered together in the bootstrap test (1000 replicates) are shown above the branches. Species are identified by strain number when available and Genbank accession number. Morphological analysis of ASG15JUL14-6 was carried out using an Olympus IX51 epifluorescent microscope equipped with an Olympus U-CMAD3. Scale bar is 50 µm.

Table 1

^1H and ^{13}C NMR spectroscopic data for kalkipyron B (2)^{a, b}.

position	α_{C} , type	α_{H} , (J in Hz)	COSY	HMBC	NOESY ^c
1	162.1, qC				
2	99.3, qC				
3	181.0, qC				
4	118.0, qC				
5	157.2, qC				
6	29.9, CH ₂	3.29 d (7.3)	7, 17, 18	5, 7, 8	17
7	116.8, CH	5.21 ovlp	6, 17, 18	6, 9, 17	9
8	138.8, qC				
9	39.2, CH ₂	2.00 t (7.7)	10	7, 8, 10, 11, 17	
10	25.9, CH ₂	1.52 m	9, 11	8, 9	
11	38.9, CH ₂	1.93 t (7.7)	10	9, 10, 12, 13, 16	
12	137.4, qC				
13	129.0, CH	5.20 ovlp	14, 16	11, 16	11, 15
14	64.7, CH	4.58 m	13, 15	12, 13	15, 16
15	23.5, CH ₃	1.23 d (6.3)	14	13, 14	
16	16.4, CH ₃	1.67 s		11, 12, 13	
17	16.2, CH ₃	1.72 s	6	7, 8, 9	
18	10.1, CH ₃	1.96 s	6	3, 4, 5	
19	6.8, CH ₃	1.84 s		1, 2, 3	
20	55.4, CH ₃	3.93 s		1	

^aData obtained on a Varian 500 MHz instrument in CDCl₃.

^bovlp = overlapped signals.

^cdata taken in DMSO.